Danna Jennings

Best Publications

• The Parkinson Progression Marker Initiative (PPMI)

  Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  1881
  Citations

• The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

  Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  641
  Citations

• Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

  Abhinay D. Joshi;Michael J. Pontecorvo;Chrisopher M. Clark;Alan P. Carpenter

  509
  Citations

• A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

  Unknown

  500
  Citations

• Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

  Michael J. Pontecorvo;Michael D. Devous;Michael Navitsky;Ming Lu

  357
  Citations

• Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study

  R. N. Alcalay;E. Caccappolo;H. Mejia-Santana;M. X. Tang

  295
  Citations

• Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study

  P. Murali Doraiswamy;Reisa A. Sperling;R. Edward Coleman;Keith A. Johnson

  276
  Citations

• Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

  Andrew Siderowf;Danna Jennings;Shirley Eberly;David Oakes

  254
  Citations

• [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy

  Andrea Varrone;Kenneth L. Marek;Danna Jennings;Robert B. Innis;Robert B. Innis

  237
  Citations

• (123I) β-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome: Unmasking an Early Diagnosis

  Danna L. Jennings;John P. Seibyl;David Oakes;Shirley Eberly

  236
  Citations

• Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders

  B. A. Racette;S. D. Tabbal;D. Jennings;L. Good

  233
  Citations

• Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

  Danna Jennings;Andrew Siderowf;Matthew Stern;John Seibyl

  229
  Citations

• Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

  Danna Jennings;Andrew Siderowf;Matthew Stern;John Seibyl

  218
  Citations

• CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

  Ju-Hee Kang;Ju-Hee Kang;Brit Mollenhauer;Christopher S. Coffey;Jon B. Toledo

  206
  Citations

• Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

  Tanya Simuni;Andrew Siderowf;Shirley Lasch;Chris S. Coffey

  199
  Citations

• Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

  Kenneth Marek;John Seibyl;Shirley Eberly;David Oakes

  197
  Citations

• Frequency of Known Mutations in Early-Onset Parkinson Disease: Implication for Genetic Counseling: The Consortium on Risk for Early Onset Parkinson Disease Study

  Roy N. Alcalay;Elise Caccappolo;Helen Mejia-Santana;Ming Xin Tang

  182
  Citations

• Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury

  E M Mitsis;S Riggio;L Kostakoglu;D L Dickstein

  153
  Citations

• Plasma apolipoprotein A1 as a biomarker for Parkinson disease

  Judy K. Qiang;Yvette C. Wong;Andrew Siderowf;Howard I. Hurtig

  153
  Citations

• In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease

  Lana M. Chahine;Thomas G. Beach;Michael C. Brumm;Charles H. Adler

  142
  Citations